Alvand Naserghandi

Dr. Alvand Naserghandi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in New Microbes and New Infections
Verified
Journal Article
Open access
ANAlvand Naserghandi
Alvand Naserghandi
SAS.F. Allameh
S.F. Allameh
RSR. Saffarpour
R. Saffarpour

8 October 2022 in Immunopathologia Persa
Verified
Journal Article
Open access
HMHossein Majlesi
Hossein Majlesi
SSSaba Shahsavan
Saba Shahsavan
YFYeganeh Farsi
Yeganeh Farsi
ATAtena Tamimi
Atena Tamimi
SISaba Ilkhani
Saba Ilkhani
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
On 25 November 2021, the world health organization listed Omicron as a newly arisen and the fifth variant of concern (VoC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The genome sequence of Omicron showed the utmost number of mutations compared to other known VoCs up to now, and it was regarded as the only SARS-CoV-2 variant with changes in the receptor-binding domain (RBD). However, the Omicron is still detectable via previous polymerase chain reaction (PCR) tests. Clinical presentation of the disease is identical to previous VoCs, however in vitro and in vivo studies revealed a higher transmission rate. The biggest obstacles posed by Omicron are the immune escape and reduction in vaccine effectiveness, as indicated by many simulations and real-world studies. Although the efficacy of the two-dose vaccinations is suboptimal for Omicron, preliminary studies have considered the injection of a booster shot is beneficial and can decrease the risk of severe disease. All these new features of Omicron warranted close investigation of this VoC as a new chapter in the pandemic, especially with emersion of subvariants BA.4 and BA.5. This review presents a conspectus of the current knowledge on the COVID-19 Omicron variant biological, clinical, and epidemiological changes.

23 September 2025 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
Pooya HekmatiPooya Hekmati
Pooya Hekmati
NGNegar Mohammadi Ganjaroudi
Negar Mohammadi Ganjaroudi
ADArash Hassanpour Dargah
Arash Hassanpour Dargah
MJMahdiyar Jaberi
Mahdiyar Jaberi
MSMohammad Amin Siri
Mohammad Amin Siri
Abdol-Mohammad KajbafzadehAbdol-Mohammad Kajbafzadeh
Abdol-Mohammad Kajbafzadeh

9 June 2025 in Journal of lasers in medical sciences
Verified
Journal Article
Open access
PDF file
ANAlvand Naserghandi
Alvand Naserghandi
AAAmir Reza Abedi
Amir Reza Abedi
MZMohammad Amin Tofighi Zavareh
Mohammad Amin Tofighi Zavareh
MSMohammad Javad Shahsavari
Mohammad Javad Shahsavari
MSMohammad Mehdi Shadravan
Mohammad Mehdi Shadravan
FAFarzad Allameh
Farzad Allameh
Introduction: Prostate cancer is the second most prevalent cancer in men and remains a major global health concern. Traditional treatment modalities such as radical prostatectomy (RP) and radiation therapy, while effective, often result in significant morbidity, including urinary incontinence and sexual dysfunction. Methods: A narrative review was conducted to synthesize current evidence on focal laser therapy for prostate cancer. A comprehensive literature search was performed across three major databases: PubMed, Scopus, and Web of Science. The search strategy employed the following Medical Subject Headings (MeSH) terms and keywords: ("Prostatic Neoplasms" [MeSH] OR "prostate cancer") AND ("Laser Therapy" [MeSH] OR "laser ablation" OR "focal therapy"). The search was limited to studies published between 2000 and 2024. Results: The initial search retrieved 1,444 articles. After a rigorous screening of titles, abstracts, and full-texts, 79 studies met the inclusion criteria and were incorporated into the review. The selected literature enables a comprehensive and critical evaluation of the current state of research on focal laser therapy in the management of prostate cancer. Conclusion: While focal laser therapies offer promising outcomes with fewer side effects, their long-term efficacy and survival benefits remain uncertain. High-quality studies with long-term follow-up are essential to better define their role in the prostate cancer treatment landscape and inform optimal patient selection.

1 December 2024 in Therapeutic Hypothermia and Temperature Management
Verified
Journal Article
Closed access
NTNoureddin Tavassoli
Noureddin Tavassoli
AGAlireza Ghahremani
Alireza Ghahremani
KNKosar Namakin
Kosar Namakin
ANAlvand Naserghandi
Alvand Naserghandi
SMSeyed Rouhollah Miri
Seyed Rouhollah Miri
MAMohammad Abdolahad
Mohammad Abdolahad
Cancer treatment often involves excisional surgery, but this approach may leave behind minimal residual disease, leading to tumor regrowth. Proinflammatory cytokines and their role in altering residual cancerous cells postsurgery have garnered attention. The study examines how mild intraoperative cooling affects cancer cells and their gene expression. It aims to discover strategies for reducing tumor growth after surgery. Nine cases of solid tumor were included in the study, nine samples were cooled with the Peltier–Seebeck device down to12°C, and cooled and noncooled regions of tumors were analyzed using reverse transcription-polymerase chain reaction. Key transcriptomes, including neural-cadherin, cadherins ( CDH ), 70-kDa Heat Shock Protein ( HSP70 ), hypoxia-inducible factor ( HIF ), Y-Box-binding protein 1 ( YB-1 ), matrix metalloproteinase 9 ( MMP9 ), and matrix metalloproteinase 2 ( MMP2 ), were measured to assess the impact of mild hypothermia on cancer cell metabolism and cold shock responses. Analysis of cooled and noncooled regions revealed reduced MMP2/9 levels in cooled regions in five out of seven cases, indicating potential suppression of tumor invasion and metastasis. CDH-1 expression was detected in five cases, with decreased levels observed in cooled regions in most cases, suggesting a role in tumor aggressiveness. YB-1 expression was increased in six out of eight samples, possibly correlating with local recurrence and reduced overall survival times. N-Cad expression was increased in all five samples where it was detected, indicating its potential involvement in tumor cell motility and invasion. HSPs showed a mild increase in four out of five cases following cooling, potentially contributing to tumor cell resistance to cooling-induced apoptosis. Intraoperative mild cooling resulted in the downregulation of key proteins playing a role in invasion and metastasis. However, Elevated YB-1 and N-Cad expression limits cooling's universal application. Further research is necessary to comprehend cooling-related transcriptome changes and their impact on patient outcomes.

18 June 2025 in Urology Case Reports
Verified
Journal Article
Open access
FAFarzad Allameh
Farzad Allameh
NTNiki Tadayon
Niki Tadayon
MZMohammad Amin Tofighi Zavareh
Mohammad Amin Tofighi Zavareh
SSSeyed Mohammad SadrAmeli
Seyed Mohammad SadrAmeli
ANAlvand Naserghandi
Alvand Naserghandi
Renal arteriovenous malformations (AVMs) are rare and often pose diagnostic and management challenges, especially in the absence of trauma or underlying pathology. We report a case of a 33-year-old male with a long-standing renal artery aneurysm who presented with flank pain. Imaging revealed a high-flow renal AVM with multiple aneurysms, the largest measuring 30 mm. An attempted embolization was aborted due to the risk of pulmonary embolism. Open surgical repair was performed, involving ligation of the affected arterial branches. This case highlights the complexities in managing non-traumatic renal AVMs and the role of surgery when endovascular treatment is not feasible.